ELI LILLY WKN: 858560 ISIN: US5324571083 Kürzel: LLY Forum: Aktien Thema: Hauptdiskussion

ELI LILLY $LLY Q2’26 EARNINGS HIGHLIGHTS 🔹 Revenue: $23.0B (Est. $20.7B) 🟢; +48% YoY 🔹 Adj. EPS: $8.38 (Est. $6) 🟢; +33% YoY 🔹 Mounjaro: $9.9B; +91% YoY 🔹 Zepbound: $4.9B (Est. $4.6B) 🟢; +44% YoY 🔹 GM: 85.8%; +1.5pts YoY FY26 Guide: 🔹 EPS: $35.50-$36.50 (Est. $34.20) 🟢 🔹 Revenue: $85B-$87B (Est. $85.45B) 🟡 🔹 Performance Margin: 49.0%-50.5% 🔹 Tax Rate: unchanged Other Q2 Metrics: 🔹 Operating Income: $9.0B (Est. $7.28B) 🟢; +31% YoY 🔹 Net Income: $7.1B (Est. $5.42B) 🟢; +25% YoY 🔹 Key Products Revenue: $15.7B 🔸 Acquired IPR&D charges: $2.8B; Q2 EPS included a $3.03 charge Comments: 🔸 “Lilly's momentum continues, as we delivered 48% revenue growth and raised our full-year guidance” 🔸 “With our next-generation weight-loss medicine retatrutide and its complete clinical data package in hand, new manufacturing capacity coming online, and exciting new assets entering our pipeline through business development”

https://x.com/i/status/2084954966595448906

Ich denke da geht noch was wenn die Amis kommen

plus 8% bald wieder ath!

bäh und runter

unglaublich tolle zahlen in allen bereichen🚀🚀inkl ausblick

Lass mal wirken 😉

Sie hätte mehr Aufwind verdient?

$LLY Q2 EARNINGS DOUBLE BEAT + RAISE 🔥 Adj. EPS: $8.38 vs $6.01 est Sales: $22.974B vs $20.725B est Raised FY2026 Sales Guidance

DOUBLEEEE BEAAATIN

Beat 🤝

🚀🚀🚀🚀

Was jetzt??

🚀